​

Johnson & Johnson (JNJ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

JNJ Stock Forecast

Johnson & Johnson (JNJ) stock forecast, based on 40 Wall Street analysts, predicts a 12-month average price target of $249.27, with a high of $283.00 and a low of $208.00. This represents a 10.62% increase from the last price of $225.34.

$100 $140 $180 $220 $260 $300 High: $283 Avg: $249.27 Low: $208 Last Closed Price: $225.34

JNJ Stock Rating

Johnson & Johnson stock's rating consensus is Buy, based on 40 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (50.00%), 17 Hold (42.50%), 3 Sell (7.50%), and 0 Strong Sell (0.00%).

Buy
Total 40 0 3 17 20 Strong Sell Sell Hold Buy Strong Buy

JNJ Price Target Upside V Benchmarks

TypeNameUpside
StockJohnson & Johnson10.62%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks15.46%

Price Target Trends

1M3M12M
# Anlaysts6836
Avg Price Target$264.33$261.75$227.56
Last Closing Price$225.34$225.34$225.34
Upside/Downside17.30%16.16%0.99%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 265910-125
Mar, 265910-125
Feb, 265910-125
Jan, 264911-125
Dec, 254911-125
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 20, 2026Guggenheim$266.00$232.7114.31%18.04%
Apr 15, 2026Morgan Stanley$283.00$239.6618.08%25.59%
Apr 15, 2026RBC Capital$265.00$240.1010.37%17.60%
Apr 15, 2026Rick WiseStifel Nicolaus$250.00$240.104.12%10.94%
Apr 15, 2026Matt MiksicBarclays$255.00$240.106.21%13.16%
Apr 10, 2026Morgan Stanley$267.00$239.5011.48%18.49%
Mar 18, 2026Morgan Stanley$253.00$237.196.67%12.27%
Feb 03, 2026RBC Capital$255.00$233.359.28%13.16%
Jan 28, 2026Terrance FlynnMorgan Stanley$262.00$224.4416.73%16.27%
Jan 27, 2026Ilya ZubkovLoop Capital Markets$220.00$225.16-2.29%-2.37%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 20, 2026GuggenheimBuyBuyhold
Apr 15, 2026RBC CapitalOutperformOutperformhold
Apr 10, 2026Morgan StanleyOverweightOverweighthold
Mar 18, 2026Morgan StanleyOverweightOverweighthold
Mar 02, 2026Bank of America SecuritiesNeutralNeutralhold
Feb 03, 2026RBC CapitalOutperformOutperformhold
Jan 28, 2026Morgan StanleyUnderperformOverweightupgrade
Jan 23, 2026GuggenheimBuyBuyhold
Jan 22, 2026ScotiabankOutperformOutperformhold
Jan 22, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$5 $6 $7 $8 $9 $10 $11 $12 $13 $14 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$7.93$6.83$13.88$5.84$11.03----
Avg Forecast$9.83$10.05$9.92$9.95$10.57$11.04$11.53$12.21$12.80
High Forecast$9.94$10.16$9.95$10.09$10.62$11.42$12.49$12.51$13.11
Low Forecast$9.75$9.96$9.91$9.90$10.51$10.85$10.56$11.99$12.57
Surprise %-19.33%-32.04%39.92%-41.31%4.35%----

Revenue Forecast

$75B $82B $89B $96B $103B $110B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$78.74B$79.99B$85.16B$88.82B$94.19B----
Avg Forecast$94.45B$95.02B$84.75B$88.78B$90.30B$93.55B$97.02B$101.93B$106.16B
High Forecast$95.24B$95.88B$84.79B$89.21B$91.53B$94.48B$97.31B$103.85B$108.15B
Low Forecast$93.83B$94.42B$84.73B$88.58B$89.79B$92.09B$96.74B$100.50B$104.67B
Surprise %-16.63%-15.82%0.49%0.05%4.31%----

Net Income Forecast

$10B $16B $22B $28B $34B $40B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$20.88B$17.94B$35.15B$14.07B$26.80B----
Avg Forecast$17.26B$18.98B$13.33B$25.59B$27.05B$28.52B$29.51B$31.26B$32.77B
High Forecast$20.71B$22.78B$15.99B$25.83B$27.19B$29.24B$31.98B$32.03B$33.57B
Low Forecast$13.81B$15.19B$10.66B$25.35B$26.91B$27.79B$27.05B$30.69B$32.18B
Surprise %20.98%-5.49%163.79%-45.03%-0.91%----

JNJ Forecast FAQ

Is Johnson & Johnson stock a buy?

Johnson & Johnson stock has a consensus rating of Buy, based on 40 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 17 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Johnson & Johnson is a favorable investment for most analysts.

What is Johnson & Johnson's price target?

Johnson & Johnson's price target, set by 40 Wall Street analysts, averages $249.27 over the next 12 months. The price target range spans from $208 at the low end to $283 at the high end, suggesting a potential 10.62% change from the previous closing price of $225.34.

How does Johnson & Johnson stock forecast compare to its benchmarks?

Johnson & Johnson's stock forecast shows a 10.62% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the drug manufacturers - general stocks industry (15.46%).

What is the breakdown of analyst ratings for Johnson & Johnson over the past three months?

  • April 2026: 20.00% Strong Buy, 36.00% Buy, 40.00% Hold, 0% Sell, 4.00% Strong Sell.
  • March 2026: 20.00% Strong Buy, 36.00% Buy, 40.00% Hold, 0% Sell, 4.00% Strong Sell.
  • February 2026: 20.00% Strong Buy, 36.00% Buy, 40.00% Hold, 0% Sell, 4.00% Strong Sell.

What is Johnson & Johnson’s EPS forecast?

Johnson & Johnson's average annual EPS forecast for its fiscal year ending in December 2026 is $11.04, marking a 0.09% increase from the reported $11.03 in 2025. Estimates for the following years are $11.53 in 2027, $12.21 in 2028, and $12.8 in 2029.

What is Johnson & Johnson’s revenue forecast?

Johnson & Johnson's average annual revenue forecast for its fiscal year ending in December 2026 is $93.55B, reflecting a -0.69% decrease from the reported $94.19B in 2025. The forecast for 2027 is $97.02B, followed by $101.93B for 2028, and $106.16B for 2029.

What is Johnson & Johnson’s net income forecast?

Johnson & Johnson's net income forecast for the fiscal year ending in December 2026 stands at $28.52B, representing an 6.39% increase from the reported $26.8B in 2025. Projections indicate $29.51B in 2027, $31.26B in 2028, and $32.77B in 2029.